Clinical utility of fibrinogen and Fibtem A5 for predicting progression of PPH
| Clinical outcome . | Hemostatic test . | All women . | |
|---|---|---|---|
| AUC (95% CI) . | P . | ||
| Transfusion of any RBCs | Clauss fibrinogen | 0.67 (0.60-0.74) | <.001 |
| Fibtem A5 | 0.61 (0.54-0.68) | .001 | |
| Fibtem MCF | 0.62 (0.54-0.69) | .001 | |
| PT | 0.63 (0.58-0.71) | <.001 | |
| aPTT | 0.57 (0.50-0.64) | .041 | |
| Transfusion of ≥4 U RBCs | Clauss fibrinogen | 0.78 (0.67-0.88) | <.001 |
| Fibtem A5 | 0.78 (0.69-0.88) | <.001 | |
| Fibtem MCF | 0.79 (0.69-0.89) | <.001 | |
| PT | 0.74 (0.64-0.85) | <.001 | |
| aPTT | 0.61 (0.49-0.72) | .047 | |
| Transfusion of FFP | Clauss fibrinogen | 0.79 (0.70-0.87) | <.001 |
| Fibtem A5 | 0.80 (0.72-0.88) | <.001 | |
| Fibtem MCF | 0.81 (0.73-0.89) | <.001 | |
| PT | 0.61 (0.05-0.73) | .023 | |
| aPTT | 0.57 (0.46-0.68) | .17 | |
| Transfusion of ≥8 U allogeneic products (RBCs + FFP + platelets) | Clauss fibrinogen | 0.82 (0.72-0.92) | <.001 |
| Fibtem A5 | 0.80 (0.69-0.91) | <.001 | |
| Fibtem MCF | 0.80 (0.69-0.92) | <.001 | |
| PT | 0.73 (0.61-0.86) | <.001 | |
| aPTT | 0.65 (0.51-0.78) | .015 | |
| Need for an invasive procedure | Clauss fibrinogen | 0.80 (0.69-0.91) | <.001 |
| Fibtem A5 | 0.69 (0.52-0.86) | .01 | |
| Fibtem MCF | 0.71 (0.52-0.86) | .004 | |
| PT | 0.63 (0.46-0.80) | .08 | |
| aPTT | 0.62 (0.46-0.78) | .09 | |
| Total blood loss >2500 mL | Clauss fibrinogen | 0.71 (0.61-0.81) | .011 |
| Fibtem A5 | 0.75 (0.66-0.85) | <.001 | |
| Fibtem MCF | 0.75 (0.65-0.84) | <.001 | |
| PT | 0.63 (0.53-0.74) | .009 | |
| aPTT | 0.61 (0.50-0.72) | .04 | |
| Clinical outcome . | Hemostatic test . | All women . | |
|---|---|---|---|
| AUC (95% CI) . | P . | ||
| Transfusion of any RBCs | Clauss fibrinogen | 0.67 (0.60-0.74) | <.001 |
| Fibtem A5 | 0.61 (0.54-0.68) | .001 | |
| Fibtem MCF | 0.62 (0.54-0.69) | .001 | |
| PT | 0.63 (0.58-0.71) | <.001 | |
| aPTT | 0.57 (0.50-0.64) | .041 | |
| Transfusion of ≥4 U RBCs | Clauss fibrinogen | 0.78 (0.67-0.88) | <.001 |
| Fibtem A5 | 0.78 (0.69-0.88) | <.001 | |
| Fibtem MCF | 0.79 (0.69-0.89) | <.001 | |
| PT | 0.74 (0.64-0.85) | <.001 | |
| aPTT | 0.61 (0.49-0.72) | .047 | |
| Transfusion of FFP | Clauss fibrinogen | 0.79 (0.70-0.87) | <.001 |
| Fibtem A5 | 0.80 (0.72-0.88) | <.001 | |
| Fibtem MCF | 0.81 (0.73-0.89) | <.001 | |
| PT | 0.61 (0.05-0.73) | .023 | |
| aPTT | 0.57 (0.46-0.68) | .17 | |
| Transfusion of ≥8 U allogeneic products (RBCs + FFP + platelets) | Clauss fibrinogen | 0.82 (0.72-0.92) | <.001 |
| Fibtem A5 | 0.80 (0.69-0.91) | <.001 | |
| Fibtem MCF | 0.80 (0.69-0.92) | <.001 | |
| PT | 0.73 (0.61-0.86) | <.001 | |
| aPTT | 0.65 (0.51-0.78) | .015 | |
| Need for an invasive procedure | Clauss fibrinogen | 0.80 (0.69-0.91) | <.001 |
| Fibtem A5 | 0.69 (0.52-0.86) | .01 | |
| Fibtem MCF | 0.71 (0.52-0.86) | .004 | |
| PT | 0.63 (0.46-0.80) | .08 | |
| aPTT | 0.62 (0.46-0.78) | .09 | |
| Total blood loss >2500 mL | Clauss fibrinogen | 0.71 (0.61-0.81) | .011 |
| Fibtem A5 | 0.75 (0.66-0.85) | <.001 | |
| Fibtem MCF | 0.75 (0.65-0.84) | <.001 | |
| PT | 0.63 (0.53-0.74) | .009 | |
| aPTT | 0.61 (0.50-0.72) | .04 | |
Data are ROC AUC (95% CI).